BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 27479745)

  • 21. Methylation of p16 ink4a promoter is independent of human papillomavirus DNA physical state: a comparison between cervical pre-neoplastic and neoplastic samples.
    Carestiato FN; Amaro-Filho SM; Moreira MAM; Cavalcanti SMB
    Mem Inst Oswaldo Cruz; 2018 Dec; 114():e180456. PubMed ID: 30569945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
    Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
    Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies.
    Nieh S; Chen SF; Chu TY; Lai HC; Lin YS; Fu E; Gau CH
    Gynecol Oncol; 2005 Apr; 97(1):35-40. PubMed ID: 15790434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus DNA, HPV L1 capsid protein and p16
    Hu H; Zhao J; Yu W; Zhao J; Wang Z; Jin L; Yu Y; Han L; Wang L; Zhu H; Li F
    Arch Gynecol Obstet; 2019 Jan; 299(1):141-149. PubMed ID: 30390110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study.
    Tsoumpou I; Valasoulis G; Founta C; Kyrgiou M; Nasioutziki M; Daponte A; Koliopoulos G; Malamou-Mitsi V; Karakitsos P; Paraskevaidis E
    Gynecol Oncol; 2011 Apr; 121(1):49-53. PubMed ID: 21194734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TOP2A/MCM2, p16
    Del Moral-Hernández O; Hernández-Sotelo D; Alarcón-Romero LDC; Mendoza-Catalán MA; Flores-Alfaro E; Castro-Coronel Y; Ortiz-Ortiz J; Leyva-Vázquez MA; Ortuño-Pineda C; Castro-Mora W; Illades-Aguiar B
    BMC Cancer; 2021 Jan; 21(1):39. PubMed ID: 33413211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of p16 and cervical infection with high-risk human papillomavirus are not related to p53 activity in cervical intraepithelial neoplasia.
    Bragança JF; Sarian LO; Pitta DR; Maito AB; Vassallo J; Pignataro F; Andrade LA; Derchain S
    Int J Gynecol Cancer; 2008; 18(5):1060-4. PubMed ID: 18021213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using p16 immunohistochemistry to classify morphologic cervical intraepithelial neoplasia 2: correlation of ambiguous staining patterns with HPV subtypes and clinical outcome.
    Liu Y; Alqatari M; Sultan K; Ye F; Gao D; Sigel K; Zhang D; Kalir T
    Hum Pathol; 2017 Aug; 66():144-151. PubMed ID: 28705710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of correlation between p16INK4a staining, specific subtype of human papillomavirus, and progression of LSIL/CIN1 lesions: first comparative study.
    Razmpoosh M; Sansregret A; Oligny LL; Patey N; Dormoy-Raclet V; Ducruet T; Bouron-Dal Soglio D
    Am J Clin Pathol; 2014 Jul; 142(1):104-10. PubMed ID: 24926093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection.
    Li B; Hu Y; Ye F; Li Y; Lv W; Xie X
    Int J Gynecol Cancer; 2010 May; 20(4):597-604. PubMed ID: 20442590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women.
    Ordi J; Garcia S; del Pino M; Landolfi S; Alonso I; Quintó L; Torné A
    Int J Gynecol Pathol; 2009 Jan; 28(1):90-7. PubMed ID: 19047902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia.
    Piyathilake CJ; Badiga S; Chambers MM; Brill IK; Matthews R; Partridge EE
    Cancer; 2016 Sep; 122(18):2836-44. PubMed ID: 27243771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
    Stănculescu R; Brătilă E; Bauşic V; Vlădescu T
    Rom J Morphol Embryol; 2013; 54(4):1061-5. PubMed ID: 24399002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification of high-grade cervical intraepithelial neoplasia by p16
    Vink FJ; Dick S; Heideman DAM; De Strooper LMA; Steenbergen RDM; Lissenberg-Witte BI; ; Floore A; Bonde JH; Oštrbenk Valenčak A; Poljak M; Petry KU; Hillemanns P; van Trommel NE; Berkhof J; Bleeker MCG; Meijer CJLM
    Int J Cancer; 2021 Aug; 149(3):707-716. PubMed ID: 33729551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study.
    Prétet JL; Jacquard AC; Carcopino X; Monnier-Benoit S; Averous G; Soubeyrand B; Leocmach Y; Mougin C; Riethmuller D;
    Int J Cancer; 2008 Jan; 122(2):424-7. PubMed ID: 17893883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia.
    Kalof AN; Evans MF; Simmons-Arnold L; Beatty BG; Cooper K
    Am J Surg Pathol; 2005 May; 29(5):674-9. PubMed ID: 15832093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia.
    Holladay EB; Logan S; Arnold J; Knesel B; Smith GD
    Cancer; 2006 Dec; 108(6):451-61. PubMed ID: 17078096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
    Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.